Published online Jun 18, 2021. doi: 10.5500/wjt.v11.i6.187
Peer-review started: February 1, 2021
First decision: March 8, 2021
Revised: March 17, 2021
Accepted: May 24, 2021
Article in press: May 24, 2021
Published online: June 18, 2021
Processing time: 131 Days and 5.7 Hours
Core Tip: Liver transplantation (LT) is a lifesaving procedure for patients with acute liver failure (ALF). Its use, however, is constrained by the absence of reliable prognostic models that hampers the selection of transplant candidates in a timely and precise manner. The survival of medically treated ALF patients has increased over time, but the criteria for LT remain the same. No clear advantage of LT in acetaminophen-associated ALF appears to be present. The other problems associated with LT in ALF are diagnostic dilemmas, shortage of graft, waiting list contraindications, vaguely defined delisting criteria, pre-transplant assessment time limits, ethical concerns, and comparatively poor post-transplant outcomes. Therefore, there is a desperate need to establish accurate prognostic models and explore the roles of alternative therapies to enhance transplant-free survival and fill the gap produced by the shortage of graft.
